Stockreport

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals, Inc.  (PHAT) 
Last phathom pharmaceuticals, inc. earnings: 3/19 08:31 am Check Earnings Report
PDF First patient dosed, with topline results expected in 2027pHalcon-EoE-201 is the first large, well-controlled clinical trial of an acid secretory treatment in EoE FLORH [Read more]